```html

Zollinger‑Ellison Syndrome – Gastrin‑Producing Neuroendocrine Tumor

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing neuroendocrine tumors (gastrinomas) develop, most often in the pancreas or duodenum. The excess gastrin stimulates the stomach lining to secrete large volumes of acid, leading to severe peptic ulcer disease and a host of gastrointestinal symptoms.

• Incidence: Approximately 0.5–2 cases per million people per year.
• Prevalence: About 1–3 % of all patients with ulcers have ZES; the condition accounts for < 0.1 % of all pancreatic neuroendocrine tumors.
• Age & gender: Most patients are diagnosed between 30–60 years of age. Slight male predominance (≈55 % male).
• Inheritance: ~25 % are associated with familial multiple endocrine neoplasia type 1 (MEN 1) syndrome.

Because the disease is uncommon, many patients experience a delay of months to years before diagnosis.

Symptoms

Symptoms arise from excess gastric acid and from the tumor itself. The clinical picture can vary, but the most common complaints are:

Gastro‑intestinal (acid‑related) symptoms

• Refractory/recurring peptic ulcers: Often multiple, located beyond the duodenum (e.g., jejunum, ileum).
• Abdominal pain: Burning or gnawing, worsens on an empty stomach.
• Diarrhea: Acid inactivates pancreatic enzymes, leading to malabsorption.
• Steatorrhea (fatty stools): Result of impaired fat digestion.
• Nausea & vomiting: May be triggered by ulcer pain or gastric outlet obstruction.
• Heartburn & gastro‑esophageal reflux disease (GERD): Due to high acid load.

Systemic symptoms

• Weight loss: From malabsorption and chronic illness.
• Fatigue & anemia: Chronic bleeding from ulcers.
• Dehydration: From persistent diarrhea.
• Osteoporosis: Long‑term acid excess can impair calcium absorption.

Symptoms related to tumor location

• Pancreatic gastrinoma: May cause a palpable abdominal mass or back pain.
• Duodenal gastrinoma: Often small and asymptomatic until acid effects appear.
• Metastatic disease (liver, lymph nodes): Can cause right‑upper‑quadrant discomfort, jaundice, or hepatic dysfunction.

Causes and Risk Factors

ZES results from a neoplastic (tumor) proliferation of gastrin‑secreting G‑cells. The underlying mechanisms include:

• Genetic mutations:
  • MEN 1 gene (menin) mutation – accounts for most hereditary cases.
  • Rare sporadic mutations in the CDKN1B or APC genes.
• Non‑genetic factors: Currently none are proven; the disease is considered essentially sporadic when not linked to MEN 1.

Risk groups

• Patients with known MEN 1 syndrome.
• Family members of individuals diagnosed with ZES (genetic counseling recommended).
• Individuals with unexplained, multiple, or refractory peptic ulcers.

Diagnosis

Timely diagnosis hinges on recognizing the pattern of severe acid‑related disease and confirming hypergastrinemia.

Laboratory tests

• Fasting serum gastrin level: > 1,000 pg/mL (normal < 100 pg/mL) is highly suggestive. Levels > 150 pg/mL with a gastric pH > 2 are diagnostic.
• Secretin stimulation test: In ZES, gastrin paradoxically rises after intravenous secretin (≥ 120 pg/mL increase).
• Gastric pH measurement: < 2 confirms acid hypersecretion.

Imaging studies

• Somatostatin receptor imaging (Ga‑68 DOTATATE PET/CT): Most sensitive for locating gastrinomas and metastases.
• Endoscopic ultrasound (EUS): Detects small (< 2 cm) pancreatic or duodenal lesions.
• CT or MRI abdomen: Used for staging and surgical planning.
• Selective arterial secretagogue injection (SASI) test: Rarely used; helps pinpoint tumor location when non‑invasive imaging is inconclusive.

Endoscopic evaluation

• Upper endoscopy (EGD) to document ulcer number, size, and location; biopsy to exclude malignancy in atypical lesions.

Reference: Mayo Clinic; NIH Rare Diseases Clinical Research Network; NCCN Guidelines for Neuroendocrine Tumors.

Treatment Options

Medical therapy – controlling acid hypersecretion

• High‑dose proton pump inhibitors (PPIs): Omeprazole 60–120 mg/day, Lansoprazole 60–90 mg/day, or equivalent. PPIs are the cornerstone; they heal ulcers and improve quality of life.
• H2‑receptor antagonists: Used only when PPIs are not tolerated; generally less effective.
• Antacids: Adjunctive for breakthrough symptoms.

Definitive therapy – addressing the tumor

1. Surgical resection: Preferred when the tumor is localized (< 2 cm) and resectable. Options include:
   • Enucleation of small duodenal gastrinomas.
   • Pancreatoduodenectomy (Whipple) for larger pancreatic lesions.
2. Somatostatin analogues (SSA): Octreotide or Lanreotide can suppress gastrin release and are valuable for unresectable or metastatic disease.
3. Targeted therapies:
   • Everolimus (mTOR inhibitor) – demonstrated progression‑free survival benefit in advanced neuroendocrine tumors.
   • Sunitinib (tyrosine‑kinase inhibitor) – approved for pancreatic neuroendocrine tumors.
4. Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; useful for metastatic disease.
5. Chemotherapy: Reserved for high‑grade or rapidly progressive tumors; regimens often include streptozocin + 5‑FU or temozolomide.
6. Liver‑directed therapies: Radiofrequency ablation, transarterial embolization, or surgical metastasectomy for hepatic involvement.

Lifestyle & supportive measures

• Eat small, frequent meals; avoid large fatty meals that exacerbate diarrhea.
• Limit alcohol and caffeine, which increase acid secretion.
• Stay hydrated; oral rehydration solutions may be needed with chronic diarrhea.
• Supplement calcium, vitamin D, and a multivitamin if malabsorption is present.
• Smoking cessation – reduces ulcer risk and improves overall prognosis.

Living with Zollinger‑Ellison syndrome – gastrin‑producing neuroendocrine tumor

Long‑term management focuses on symptom control, monitoring for recurrence, and maintaining nutritional health.

• Regular follow‑up: Every 3–6 months initially, then annually if stable. Includes serum gastrin, gastric pH, and imaging (CT or MRI).
• Medication adherence: PPIs often require lifelong use; never stop abruptly without physician guidance.
• Track symptoms: Keep a diary of abdominal pain, stool frequency, and any new signs (e.g., vomiting).
• Nutrition: Consider a dietitian‑guided low‑fat, high‑protein plan; enzyme supplements (pancrelipase) can aid digestion.
• Psychosocial support: Chronic disease can cause anxiety; patient support groups (e.g., NET Patient Foundation) are valuable.
• Genetic counseling: Recommended for patients with MEN 1 or a family history.

Prevention

Because ZES is primarily driven by genetic mutations and sporadic tumor development, true primary prevention is limited. Strategies to reduce disease impact include:

• Early detection in high‑risk families through genetic testing for MEN 1.
• Prompt evaluation of persistent or recurrent peptic ulcers, especially if they are atypical (distal duodenum, jejunum).
• Avoiding long‑term NSAID or aspirin use without gastro‑protective therapy.

Complications

If left untreated or inadequately managed, ZES can lead to serious health problems:

• Gastrointestinal bleeding: From ulcer erosion; may require transfusion or endoscopic therapy.
• Perforated ulcer: Surgical emergency with risk of peritonitis.
• Gastric outlet obstruction: Caused by edema or tumor infiltration.
• Malabsorption & nutritional deficiencies: Resulting in weight loss, anemia, osteopenia.
• Metastatic disease: Liver, lymph nodes, or bone metastases occur in 30‑50 % of sporadic cases.
• Secondary gastric cancer: Chronic acid exposure slightly raises risk.

When to Seek Emergency Care

Prompt treatment can be life‑saving and may prevent long‑term complications.

---

Sources: Mayo Clinic. “Zollinger‑Ellison syndrome.”; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison syndrome.”; NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Pancreatic Tumors (2023); WHO Classification of Tumours of the Digestive System (2022); Cleveland Clinic. “Neuroendocrine Tumors.”

```